Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.43
DEPO's Cash to Debt is ranked higher than
74% of the 1152 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.37 vs. DEPO: 2.43 )
DEPO' s 10-Year Cash to Debt Range
Min: 0.84   Max: No Debt
Current: 2.43

Equity to Asset 0.51
DEPO's Equity to Asset is ranked higher than
62% of the 1034 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.58 vs. DEPO: 0.51 )
DEPO' s 10-Year Equity to Asset Range
Min: -1.33   Max: 0.89
Current: 0.51

-1.33
0.89
Interest Coverage 9.90
DEPO's Interest Coverage is ranked higher than
54% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 176.76 vs. DEPO: 9.90 )
DEPO' s 10-Year Interest Coverage Range
Min: 1.73   Max: 9999.99
Current: 9.9

1.73
9999.99
F-Score: 3
Z-Score: 5.34
M-Score: -0.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 60.66
DEPO's Operating margin (%) is ranked higher than
99% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.84 vs. DEPO: 60.66 )
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91   Max: 72.49
Current: 60.66

-12972.91
72.49
Net-margin (%) 33.75
DEPO's Net-margin (%) is ranked higher than
97% of the 1102 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.10 vs. DEPO: 33.75 )
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35   Max: 75.05
Current: 33.75

-14964.35
75.05
ROE (%) 59.62
DEPO's ROE (%) is ranked higher than
99% of the 1129 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.93 vs. DEPO: 59.62 )
DEPO' s 10-Year ROE (%) Range
Min: -1132.2   Max: 539.95
Current: 59.62

-1132.2
539.95
ROA (%) 22.80
DEPO's ROA (%) is ranked higher than
97% of the 1161 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.32 vs. DEPO: 22.80 )
DEPO' s 10-Year ROA (%) Range
Min: -201.37   Max: 73.87
Current: 22.8

-201.37
73.87
ROC (Joel Greenblatt) (%) 3012.48
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 1156 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.14 vs. DEPO: 3012.48 )
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2396.53   Max: 7997.51
Current: 3012.48

-2396.53
7997.51
Revenue Growth (3Y)(%) 35.50
DEPO's Revenue Growth (3Y)(%) is ranked higher than
96% of the 932 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. DEPO: 35.50 )
DEPO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -69.7   Max: 420.5
Current: 35.5

-69.7
420.5
EBITDA Growth (3Y)(%) 43.20
DEPO's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 839 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.70 vs. DEPO: 43.20 )
DEPO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55.8   Max: 84.2
Current: 43.2

-55.8
84.2
EPS Growth (3Y)(%) 16.50
DEPO's EPS Growth (3Y)(%) is ranked higher than
83% of the 811 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. DEPO: 16.50 )
DEPO' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.5   Max: 180.9
Current: 16.5

-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

DEPO Guru Trades in Q1 2014

Paul Tudor Jones 63,632 sh (+220.52%)
Jim Simons Sold Out
Steven Cohen 17,403 sh (-99.07%)
» More
Q2 2014

DEPO Guru Trades in Q2 2014

George Soros 75,600 sh (New)
Joel Greenblatt 937,085 sh (New)
Paul Tudor Jones 40,112 sh (-36.96%)
» More
Q3 2014

DEPO Guru Trades in Q3 2014

Steven Cohen 448,900 sh (New)
Joel Greenblatt 1,637,713 sh (+74.77%)
Paul Tudor Jones 64,690 sh (+61.27%)
George Soros Sold Out
» More
Q4 2014

DEPO Guru Trades in Q4 2014

Joel Greenblatt 1,218,263 sh (-25.61%)
Paul Tudor Jones 42,365 sh (-34.51%)
Steven Cohen 151,800 sh (-66.18%)
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 14.20
DEPO's P/E(ttm) is ranked higher than
94% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 64.60 vs. DEPO: 14.20 )
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36   Max: 121.85
Current: 14.2

2.36
121.85
Forward P/E 23.92
DEPO's Forward P/E is ranked higher than
82% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DEPO: 23.92 )
N/A
PE(NRI) 14.20
DEPO's PE(NRI) is ranked higher than
95% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 61.40 vs. DEPO: 14.20 )
DEPO' s 10-Year PE(NRI) Range
Min: 2.36   Max: 123.38
Current: 14.2

2.36
123.38
P/B 4.20
DEPO's P/B is ranked higher than
63% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.13 vs. DEPO: 4.20 )
DEPO' s 10-Year P/B Range
Min: 2   Max: 48.18
Current: 4.2

2
48.18
P/S 4.50
DEPO's P/S is ranked higher than
54% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.19 vs. DEPO: 4.50 )
DEPO' s 10-Year P/S Range
Min: 1.38   Max: 752
Current: 4.5

1.38
752
EV-to-EBIT 5.09
DEPO's EV-to-EBIT is ranked higher than
99% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 43.18 vs. DEPO: 5.09 )
DEPO' s 10-Year EV-to-EBIT Range
Min: -208.4   Max: 130
Current: 5.09

-208.4
130
Shiller P/E 51.90
DEPO's Shiller P/E is ranked higher than
83% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DEPO: 51.90 )
DEPO' s 10-Year Shiller P/E Range
Min: 21.62   Max: 123.75
Current: 51.9

21.62
123.75
Current Ratio 10.74
DEPO's Current Ratio is ranked higher than
95% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.13 vs. DEPO: 10.74 )
DEPO' s 10-Year Current Ratio Range
Min: 0.29   Max: 12.5
Current: 10.74

0.29
12.5
Quick Ratio 10.59
DEPO's Quick Ratio is ranked higher than
96% of the 1100 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. DEPO: 10.59 )
DEPO' s 10-Year Quick Ratio Range
Min: 0.29   Max: 12.5
Current: 10.59

0.29
12.5
Days Inventory 203.24
DEPO's Days Inventory is ranked higher than
61% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 148.81 vs. DEPO: 203.24 )
DEPO' s 10-Year Days Inventory Range
Min: 93.22   Max: 613.73
Current: 203.24

93.22
613.73
Days Sales Outstanding 25.25
DEPO's Days Sales Outstanding is ranked higher than
94% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 89.68 vs. DEPO: 25.25 )
DEPO' s 10-Year Days Sales Outstanding Range
Min: 12.13   Max: 54004.13
Current: 25.25

12.13
54004.13

Valuation & Return

vs
industry
vs
history
Price/Net Cash 7.18
DEPO's Price/Net Cash is ranked higher than
93% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DEPO: 7.18 )
DEPO' s 10-Year Price/Net Cash Range
Min: 4.23   Max: 53
Current: 7.18

4.23
53
Price/Net Current Asset Value 5.65
DEPO's Price/Net Current Asset Value is ranked higher than
91% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DEPO: 5.65 )
DEPO' s 10-Year Price/Net Current Asset Value Range
Min: 2.62   Max: 67
Current: 5.65

2.62
67
Price/Tangible Book 5.19
DEPO's Price/Tangible Book is ranked higher than
69% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. DEPO: 5.19 )
DEPO' s 10-Year Price/Tangible Book Range
Min: 2.54   Max: 87
Current: 5.19

2.54
87
Price/DCF (Projected) 9.58
DEPO's Price/DCF (Projected) is ranked higher than
75% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. DEPO: 9.58 )
DEPO' s 10-Year Price/DCF (Projected) Range
Min: 1.49   Max: 335
Current: 9.58

1.49
335
Price/Median PS Value 1.20
DEPO's Price/Median PS Value is ranked higher than
76% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. DEPO: 1.20 )
DEPO' s 10-Year Price/Median PS Value Range
Min: 0.57   Max: 54.55
Current: 1.2

0.57
54.55
Price/Graham Number 1.65
DEPO's Price/Graham Number is ranked higher than
87% of the 1267 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.40 vs. DEPO: 1.65 )
DEPO' s 10-Year Price/Graham Number Range
Min: 0.69   Max: 7.48
Current: 1.65

0.69
7.48
Earnings Yield (Greenblatt) 19.80
DEPO's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. DEPO: 19.80 )
DEPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 251.9
Current: 19.8

0.8
251.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany,
DepoMed Inc was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Reports Second Quarter 2009 Financial Results Jul 30 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
DepoMed Set To Grow On 'Transformative' Nucynta Deal Apr 23 2015
Street Talk: DEPO under the radar Apr 22 2015
Coverage initiated on DepoMed by Piper Jaffray Apr 22 2015
Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing... Apr 13 2015
Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing... Apr 13 2015
Conditions are ripe for the intermediate-term speculator Apr 09 2015
Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER... Apr 02 2015
DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of... Apr 02 2015
Depomed Announces Closing of Acquisition of U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER... Apr 02 2015
Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of... Mar 17 2015
DEPOMED INC Files SEC form 8-K, Entry into a Material Definitive Agreement Mar 12 2015
Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of... Mar 12 2015
DEPOMED INC Financials Mar 05 2015
Depomed To Present At 27th Annual Roth Conference Mar 03 2015
10-K for Depomed, Inc. Feb 28 2015
DEPOMED INC Files SEC form 10-K, Annual Report Feb 26 2015
Depomed Reports Fourth Quarter and Full Year 2014 Financial Results Feb 25 2015
The Nasdaq is doing the most bullish thing a market can do Feb 24 2015
Depomed: The Next Big Specialty Pharma Success Story Feb 24 2015
Stocks Mixed As Yellen Speaks; Depomed, Home Depot, BHP Surge Feb 24 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK